Health
Danish pharmaceutical company Novo Nordisk introduced its diabetes drug Ozempic to the Indian market, pricing the 0.25 mg weekly injection at ₹2,200.
Health
Around 89.8 million adults aged 20-79 years live with diabetes in India as of 2024, marking the second-highest burden worldwide.
Health
The age-standardised prevalence stands at 10.5 percent, with 43 percent of cases undiagnosed, equating to about 38.6 million individuals unaware of their condition.
Health
The U.S. Food and Drug Administration approved Ozempic, a once-weekly injectable, in 2017 for type 2 diabetes.
Health
The drug has become a bestseller globally and users apply it off-label for weight loss due to its appetite-suppressing effects.
Health
Meanwhile, Novo’s Wegovy, which contains the same active ingredient semaglutide as Ozempic, carries approval for weight loss.